Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO)

Affinity Asset Advisors LLC purchased a new stake in shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 89,222 shares of the company’s stock, valued at approximately $432,000. Affinity Asset Advisors LLC owned 1.82% of NeuroBo Pharmaceuticals at the end of the most recent quarter.

NeuroBo Pharmaceuticals Trading Up 0.3 %

Shares of NeuroBo Pharmaceuticals stock opened at $3.20 on Wednesday. The firm’s 50-day moving average is $3.80 and its two-hundred day moving average is $3.99. NeuroBo Pharmaceuticals, Inc. has a 1 year low of $2.90 and a 1 year high of $6.75.

NeuroBo Pharmaceuticals (NASDAQ:NRBO) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.38) by ($0.47). Equities analysts expect that NeuroBo Pharmaceuticals, Inc. will post -4.39 EPS for the current fiscal year.

NeuroBo Pharmaceuticals Company Profile

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.